Showing 8321-8330 of 20418 results for "".
Weighing the Role of Network Meta-analysis for Choosing Biologic Therapies in Psoriatic Disease
https://reachmd.com/programs/practical-dermatology/weighing-the-role-of-network-meta-analysis-for-choosing-biologic-therapies-in-psoriatic-disease/18189/There’s no paucity of studies for biologic therapies used to treat psoriatic disease, but the number of head-to-head trials comparing these agents is limited. Enter network meta-analysis, a statistical methodology that has emerged over the past few years to compare medication. Philip Mease, MD, a clWhy Is Psoriatic Arthritis Often Misdiagnosed?
https://reachmd.com/programs/beyond-skin-deep/why-is-psoriatic-arthritis-often-misdiagnosed/10141/Gout or psoriatic arthritis? One patient's distressing experience on the road to diagnosis may have you thinking twice about the possibility of PsA.Breakthroughs in Generalized Pustular Psoriasis Treatment: Exploring Current & Emerging Approaches
https://reachmd.com/programs/clinicians-roundtable/breakthroughs-in-generalized-pustular-psoriasis-treatment-exploring-current-emerging-approaches/15833/Generalized pustular psoriasis is a variant of psoriasis that, if left untreated, could become fatal. How might emerging therapies help?Prescribing Controlled Substances Through Telehealth: Post-Pandemic Considerations
https://reachmd.com/programs/neurofrontiers/prescribing-controlled-substances-through-telehealth-post-pandemic-considerations/15448/Can we continue to safely prescribe controlled substances post-pandemic? And when should we refer to in-person practitioners?Advancing MS Care: Evolving Treatments and High-Efficacy Approaches
https://reachmd.com/programs/neurofrontiers/program-name/36356/Multiple sclerosis (MS) treatment has transformed dramatically, with a wide range of high-efficacy options currently available. Dr. Marisa McGinley, a neurologist at the Cleveland Clinic, explores how advancements in drug availability, administration methods, and efficacy are reshaping care, with aHow Muscarinic Therapies Are Redefining Schizophrenia Care
https://reachmd.com/programs/neurofrontiers/muscarinic-therapies-schizophrenia-care/39941/Unlike traditional dopamine-targeting antipsychotics that often come with weight gain, motor symptoms, and metabolic side effects, the first-in-class muscarinic agent xanomeline-trospium offers a favorable side effect profile while addressing both positive and negative symptoms of schizophrenia. JoiHow Real-World Adherence Is Shaping Preventive Migraine Treatment
https://reachmd.com/programs/neurofrontiers/real-world-adherence-preventive-migraine-treatment/49110/Real-world adherence is emerging as a critical factor in optimizing preventive migraine care, particularly as traditional oral therapies continue to show high discontinuation rates due to tolerability challenges and delayed efficacy. To learn more about how side effects, patient expectations, and liTrust in MSLs: What Physicians Value Most
https://reachmd.com/programs/maps-chats/trust-msls-physicians-value/56809/Trust is foundational to effective scientific communication—but what factors actually drive it? Find out as Dr. Matt Birnholz speaks with Dr. Justin O’Rourke, a recent business psychology PhD graduate from The Chicago School, about his research on physician perceptions of medical science liaisons (MUnderstanding Safety Profiles of ROS1 TKIs in Advanced Non-Small Cell Lung Cancer
https://reachmd.com/programs/Audioabstracts/understanding-safety-profiles-of-ros1-tkis-in-advanced-non-small-cell-lung-cancer/54576/Targeted therapies have transformed care for patients with ROS1-rearranged advanced non-small cell lung cancer, but long-term treatment makes safety and tolerability critical. In this AudioAbstract, Ryan Quigley breaks down a 2025 systematic review examining toxicity profiles across seven ROS1 tyrosHow ctDNA and Liquid Biopsy Are Shaping Early Detection of Breast Cancer Progression
https://reachmd.com/programs/frontlines-metastatic-breast-cancer/ctdna-liquid-biopsy-breast-cancer-progression/48711/From real-time treatment decisions to the promise of minimal residual disease (MRD) detection, circulating tumor DNA (ctDNA) and liquid biopsy are transforming metastatic breast cancer care. In this expert-led discussion, Ashley Baker sits down with Dr. Nicholas McAndrew, a hematologist-oncologist a